SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS
Pieris Pharmaceuticals, Inc. (PIRS)
NASDAQ:AMEX Investor Relations:
ir.pieris.com
Company Research
Source: GlobeNewswire
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company. Click here for more information https://monteverdelaw.com/case/pieris-pharmaceuticals-inc/. It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask: Do you file class actions and go to Court?When was the last time you recovered money for shareholders?What cases did you recover money in and how much? About Monteverde & Associates PC Our firm lit
Show less
Read more
Impact Snapshot
Event Time:
PIRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PIRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PIRS alerts
High impacting Pieris Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PIRS
News
- Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial OfficerGlobeNewswire
- Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations [Yahoo! Finance]Yahoo! Finance
- PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to ShareholdersBusiness Wire
- Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023) [Yahoo! Finance]Yahoo! Finance
- We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
PIRS
Earnings
- 11/14/23 - In-Line
PIRS
Sec Filings
- 11/5/24 - Form S-4/A
- 10/29/24 - Form S-4/A
- 10/28/24 - Form 4
- PIRS's page on the SEC website